OBJECTIVE: To study the value of serum S100 protein in the diagnosis of radiation-induced brain injury in astrocytoma patients. METHODS: Serum S100 protein levels were detected by enzyme-linked immunosorbent assay in 86 astrocytoma patients in the course of radiotherapy. RESULTS: The positivity rates of serum S100 protein before, in the middle of and after radiotherapy were 0, 9.3% (8/86) and 19.8% (17/86), respectively, showing significant differences (P<0.05) between these time points for measurement. CONCLUSION: High levels of serum S100 protein are associated with radiation-induced brain injury in astrocytoma patients and may serve as the marker for early diagnosis of the injury.
OBJECTIVE: To study the value of serum S100 protein in the diagnosis of radiation-induced brain injury in astrocytomapatients. METHODS: Serum S100 protein levels were detected by enzyme-linked immunosorbent assay in 86 astrocytomapatients in the course of radiotherapy. RESULTS: The positivity rates of serum S100 protein before, in the middle of and after radiotherapy were 0, 9.3% (8/86) and 19.8% (17/86), respectively, showing significant differences (P<0.05) between these time points for measurement. CONCLUSION: High levels of serum S100 protein are associated with radiation-induced brain injury in astrocytomapatients and may serve as the marker for early diagnosis of the injury.
Authors: Wolfgang Gartner; Aysegül Ilhan; Dashurie Neziri; Wolfgang Base; Michael Weissel; Adelheid Wöhrer; Harald Heinzl; Thomas Waldhör; Ludwig Wagner; Matthias Preusser Journal: Neuro Oncol Date: 2010-04-08 Impact factor: 12.300